# 510(k) Summary

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter name, address, contact

Roche Diagnostics 9115 Hague Road Indianapolis, IN 46250

Contact person: Stephanie Greeman   
• • Phone: (317) 521-2458 FAX: (317) 521-2324 email: stephanie.greeman@roche.com   
Secondary contact :   
Kay Taylor   
• • Phone: (317) 521-3544 FAX: (317) 521-2324 email: kay.taylor@roche.com

Date Prepared: June 17, 2008

# Device Name

Proprietary name: (1) Elecsys Anti-TSHR Immunoassay (2) Elecsys PreciControl ThyroAB

Common name: (1) Anti-TSHR Assay ) PreciControl ThyroAB

Classification name: (1) System, Test, Thyroid Autoantibody (2) Single (specified) analyte controls (Assayed and Unassayed)

# 510(k) Summary, Continued

# Device Description

(1) The Elecsys Anti-TSHR immunoassay is a three step competition principle immunoassay with streptavidin-coated microparticles and electrochemiluminescence detection. Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve provided with the reagent bar code.

() The Elecsys PreciControl ThyroAB is a lyophilized product consisting of human serum with added Anti-TSHR antibody (human) in two concentration ranges. During manufacture, the antibody is spiked into the matrix at the desired concentration levels.

NoThe   aly ol  a ey.

# Intended use / Indications for Use

(1) Elecsys Anti-TSHR immunoassay: Immunoassay for the in vitro   
quantitative determination of autoantibodies to TSH receptor in human serum using a human thyroid stimulating monoclonal antibody. The anti-TSH receptor determination is used in the assessment of patients with suspect Graves' disease (autoimmune hyperthyroidism).   
The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

(2) Elecsys PreciControl ThyroAB is used for quality control of the Elecsys Anti-TSHR immunoassay on the Elecsys and cobas e immunoassay analyzers.

# Substantial equivalence

The Elecsys Anti-TSHR Test System is substantially equivalent to the following cleared device:

(1) Elecsys Anti-TSHR Immunoassay is equivalent to the BRAHMS LUMItest TRAK human Assay (K033454). Both products are intended for use in the quantitative determination of autoantibodies to TSH receptor in human serum.

(2) Elecsys PreciControl ThyroAB is equivalent to the controls contained in the BRAHMS LUMItest TRAK human Assay Kit (K033454).

# 510(k) Summary, Continued

Substantial equivalence - comparison

The following table compares the Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination ofautoantibodies to TSH receptor inhuman serum using a human thyroidstimulating monoclonal antibody.The anti-TSH receptordetermination is used in theassessment of patients with suspectGraves&#x27; disease (autoimmunehyperthyroidism).The electrochemiluminescenceimmunoassay &quot;ECLIA&quot; is intendedfor use on Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>Luminescence receptor assay (LRA)for the quantitative determination ofantibodies to the human thyrotropin(TSH) receptor.</td></tr><tr><td rowspan=1 colspan=1>Indication forUse</td><td rowspan=1 colspan=1>See intended use.</td><td rowspan=1 colspan=1>The measurement of TSH receptorautoantibodies is used in theassessment of patients with suspectGraves&#x27; disease (autoimmunehyperthyroidism).</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Competition principle</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>DetectionProtocol</td><td rowspan=1 colspan=1>electrochemiluminescenceimmunoassay (ECLIA)</td><td rowspan=1 colspan=1>Luminescence receptor assay (LRA)</td></tr><tr><td rowspan=1 colspan=1>Traceability/Standardization</td><td rowspan=1 colspan=1>Standardized against NIBSC 1st IS90/672 Standard</td><td rowspan=1 colspan=1>WHO 1s International referencematerial, 90/672 for TSAb</td></tr><tr><td rowspan=1 colspan=1>CalibrationInterval</td><td rowspan=1 colspan=1>•  DailyAs required: e.g. quality controlfindings outside the specifiedlimits</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>same</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalencecomparison

The following table compares the Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td>Immunoassay Comparisony contimuedes</td></tr><tr><td>Reature EleesyS Anti-TSHR Assay Predicate Device BRAHMS LUMItest TRAK humani Assay (K033454) </td></tr></table>

<table><tr><td rowspan=1 colspan=1>Reagent Stability</td><td rowspan=1 colspan=1>Unopened up to the statedexpiration date stored at 2 - 8°COn the analyzer: 72 hours ifcontinuously stored onboard; or 2weeks including up to 56 hours intotal onboard if stored alternatelyin the refrigerator and on theanalyzer</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Calibrator</td><td rowspan=1 colspan=1>Anti-TSHR calibrators 1 and 2supplied with kit</td><td rowspan=1 colspan=1>TRAK standards supplied with kit</td></tr><tr><td rowspan=1 colspan=1>Controls</td><td rowspan=1 colspan=1>Elecsys PreciControl ThyroAB</td><td rowspan=1 colspan=1>TRAC controls I and II supplied withkit</td></tr><tr><td rowspan=1 colspan=1>Pretreatment</td><td rowspan=1 colspan=1>Pretreatment 1: buffer solutionPretreatment 2: empty bottle forpretreatment reagent (PTR)reconstituted with pretreatmentbuffer (PTB)PTR: pretreatment reagentPTB: pretreatment buffer</td><td rowspan=1 colspan=1>Buffer for incubation of samplesBuffer for reconstitution of tracerTracer: luminescence-labeled b-TSH</td></tr><tr><td rowspan=1 colspan=1>Expected Values</td><td rowspan=1 colspan=1>Positive: &gt; 1.75 IU/L</td><td rowspan=1 colspan=1>Negative: &lt; 1 IU/LEquivocal: 1 -2 IU/LPositive: &gt; 2 IU/L</td></tr><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Elecsys 2010, MODULARANALYTICS E170, cobas e 411,cobas e 601</td><td rowspan=1 colspan=1>Luminometer</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>0.8 - 40 IU/L (defined by the limitof detection and the maximum ofthe master curve)</td><td rowspan=1 colspan=1>0.9 - 40 IU/L</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - comparison

The following table compares the performance of Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td>Precision Within-run 5.9% CV @ 4.4% CV @ 2.7% CV 1.3% CV 3.0% CV Total 6.7% CV @ 3.9% CV 1.8% CV 5.1% CV @ Within-run 7.6% CV @ 5.1% CV 1.9% CV 0.9% CV @ 3.1% CV @ Total</td><td>Elecsys 2010 and cobas e 411: 1.73 IU/L 2.57 IU/L @ 6.57 IU/L @ 25.5 IU/L @ 3.60 IU/L 1.7% CV @ 15.0 IU/L 9.7% CV @ 1.73 IU/L 2.57 IU/L @ 6.57 IU/L @ 25.5 IU/L 3.60 IU/L 2.4% CV @ 15.0 IU/L E170 and cobas e 601: 1.71 IU/L @ 2.16 IU/L @ 5.92 IU/L 24.6 IU/L 3.16 IU/L 1.4% CV @ 14.6 IU/L 11.4% CV @ 1.71 IU/L 8.7% CV @ 2.16 IU/L 3.8% CV @ 5.92 IU/L 1.9% CV @ 24.6 IU/L 5.5% CV @ 3.16 IU/L 2.4% CV @ 14.6 IU/L</td><td>Interassay Precision: Sample means 0.6 IU/L - 20.3 IU/L = %CV 4.1 - 35.1% Intra-assay Precision: Sample means 0.9 IU/L - 101.7 IU/L = % CV 2.3 - 24.2%</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - comparison

The following table compares the performance of Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td>Emunoassay.Pertormance Comparison, continued</td></tr><tr><td>Elecsys Anti TSHR Assa Predicate Device BRAHMS LUMItest TRAK human</td></tr></table>

<table><tr><td rowspan=1 colspan=1>LoQ</td><td rowspan=1 colspan=1>0.9 IU/L</td><td rowspan=1 colspan=1>0.9 IU/L</td></tr><tr><td rowspan=1 colspan=1>Limit of Blank(LoB)</td><td rowspan=1 colspan=1>≤0.5 IU/L</td><td rowspan=1 colspan=1>0.4 IU/L</td></tr><tr><td rowspan=1 colspan=1>Limit ofDetection LoD(AnalyticalSensitivity)</td><td rowspan=1 colspan=1>&lt;0.8 IU/L</td><td rowspan=1 colspan=1>NA</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSpecificity</td><td rowspan=1 colspan=1>No interference with:•  Anti-TG if less than 4000IU/mLAnti-TPO if less than 600IU/mLHuman TSH if less than1000 mIU/LHuman LH if less than10,000 mIU/mLHuman FSH if less than10,000 mIU/mLhCG if less than 50,000mIU/mL</td><td rowspan=1 colspan=1>No interference with :• Anti-TG if less than 2000U/mLAnti-TPO if less than 3000U/mL•  Human TSH if less than 1000mU/LHuman LH if less than 9000U/IHuman FSH if less than 15,000U/I.</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalencecomparison

The following table compares the performance of Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td>unoassayPertormance Comparison continued</td></tr><tr><td>Elecsys Anti-TSHRAssay Predicate Device BRAHMS LUMItest TRAK human</td></tr></table>

<table><tr><td rowspan="6">Limitations</td><td rowspan="6">The assay is unaffected by: Biotin: &lt; 10 ng/mL In patients receiving therapy with high biotin doses (i.e. &gt;5</td><td rowspan="6">0 Bilirubin: &lt; 25 mg/dL Hemoglobin: &lt; 0.4 g/dL Intralipid: &lt; 1500 mg/dL Elevated results are obtained when using samples with biotin concentrations &gt; 10 ng/mL</td><td>Hemoglobin: Concentrations: Not given Recovery: 100-125%</td></tr><tr><td>Bilirubin: Concentrations: 0.625, 1.25, 2.5,</td></tr><tr><td>5, 10, 20 mg/dL</td></tr><tr><td>Recovery: 91 - 100%</td></tr><tr><td>Lipids:</td></tr><tr><td>Concentration: dilutions prepared off of 634 mg/dL lipemic serum</td></tr><tr><td>mg/day), no sample should be taken until at least 8 hours after the last biotin administration.</td><td>Recovery: 76 - 100%</td></tr><tr><td>No interference was observed from rheumatoid factors up to a concentration of 600 IU/mL</td><td></td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - comparison

The following table compares the performance of Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td>Limitations, continued</td><td>In vitro tests were performed on 20 commonly used pharmaceuticals. No interference with the assay was found except for heparin. In samples containing heparin elevated results are obtained. The risk of interference from potential immunological interactions between test components and rare sera has been minimized by the inclusion of suitable additives.</td><td></td></tr><tr><td></td><td>In rare cases, interference due to extremely high titers of antibodies to streptavidin and ruthenium can occur.</td><td></td></tr><tr><td>findings</td><td>For diagnostic purposes, the results should always be assessed in conjunction with the patients medical history, clinical examination and other</td><td></td></tr></table>

# 510(k) Summary, Continued

Substantial equivalencecomparison

The following table compares the performance of Elecsys Anti-TSHR Immunoassay with the predicate device.

<table><tr><td rowspan=9 colspan=1>MethodComparison</td><td rowspan=1 colspan=6>A comparison of the Elecsys Anti-TSHRassay (y) with BRAHMS LUMItest TRAKhuman (x) using clinical samples gave thefollowing correlations:Number of samples measured: 212Sample concentrations were between 1.1IU/L and 40.0 IU/LPassing/Bablok:      95% CI:y = 1.183x - 0.316   Slope = 1.11 - 1.27Intercept = -0.633 to -0.079Concordance:</td></tr><tr><td rowspan=5 colspan=6>Commercial anti-TSHRCee- R           &lt;1.0  1.0-2.0  &gt;2.0IU/LIU/LIU/L&gt;1.757111991U/L≤1.75102310IU/Ltotal10942199a. 42 results were excluded from thecalculations after giving indeterminate resultson the comparative method. A moredifferentiated analysis of the samples whichgave indeterminate results in the comparativemethod shows that: 2 of the I 1 samplespositive with Elccsys Anti-TSHR have valucsfrom 1.75 - 2 1U/L., 9 of the 11 samplespositive with Elecsys Anti-TSHR have valuesabove 2 IU/L, 11 of the 31 samples negativewith Elecsys Anti-TSHR have values below 1IU/L and 20 of the 31 samples negative withElecsys Anti-TSHR have values from 1 - 1.75IU/L.</td><td rowspan=1 colspan=1>Commercial anti-TSHR</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>&lt;1.0IU/L</td><td rowspan=1 colspan=1>1.0-2.0IU/L</td><td rowspan=1 colspan=1>&gt;2.0IU/L</td></tr><tr><td rowspan=1 colspan=1>&gt;1.751U/L</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>199</td></tr><tr><td rowspan=1 colspan=1>≤1.75IU/L</td><td rowspan=1 colspan=1>102</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>109</td><td rowspan=1 colspan=1>42</td></tr><tr><td></td><td rowspan=1 colspan=2>AgreementClassification</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>%Agreement(%)</td><td rowspan=1 colspan=1>95%CI (%)</td></tr><tr><td></td><td rowspan=1 colspan=2>Neg.Agreement</td><td rowspan=1 colspan=1>102/109</td><td rowspan=1 colspan=1>93.6%</td><td rowspan=1 colspan=1>87.21097.4</td></tr><tr><td rowspan=1 colspan=6>Pos.           1997  100%       98.2 toAgreement     199                100b. % positive of Elecsys Anti-TSHR amongindeterminate results of comparative methodequals 26.2% (11/42). % negative of ElecsysAnti-TSHR among indeterminate results ofcomparative method equals 73.8% (31/42).</td><td rowspan=1 colspan=1>1997199</td></tr></table>

A correlation study was performed between the predicate KRONUS TRAb assay and the LUMItest TRAK assay. Fifty-two (52) serum samples obtained from either confirmed Graves' disease patients or patients with non-Graves' thyroid disease were tested in parallel. Overall agreement between the two assays was $7 5 . 0 \%$ .

# 510(k) Summary, Continued

# Substantial equivalencecomparison

The following table compares the calibrators supplied with the Elecsys AntiTSHR immunoassay kit with the calibrators supplied with the predicate device.

<table><tr><td>Calibrator Comparison</td></tr><tr><td>LIecsysAntE-TSHRASsaY Predicate Device BRAHMS LUMItesT TRAK human Assay (K033454))</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>6</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>human serum</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentration(Anti-TSHRantibody;human)</td><td rowspan=1 colspan=1>Calibrator 1: 1.0 IU/LCalibrator 2: 25 IU/L</td><td rowspan=1 colspan=1>Calibrator 1: 0 IU/LCalibrator 2: 1 IU/LCalibrator 3: 2 IU/LCalibrator 4: 4 IU/LCalibrator 5: 16 IU/LCalibrator 6: 40 IU/L</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2 - 8°C until expirationdate.Reconstituted:On the analyzers at 20 - 25°C:up to 3 hoursAt -20°C: up to 3 months (freezeonly once.After thawing: use only once.</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalencecomparison

The following table compares the calibrators supplied with the Elecsys AntiTSHR immunoassay kit with the calibrators supplied with the predicate device.

<table><tr><td rowspan=1 colspan=3> Calibrator Comparison, contimued</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Elecsys Anti-TSHR Assay</td><td rowspan=1 colspan=1>Predicate DeviceBRAHMS LUMItesATRAK humanAssay (K033454)</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Dissolve contents of one bottle byadding exactly 2.0 mL of distilledwater and allow to stand closed for15 minutes to reconstitute. Mixcarefully, avoiding the formation offoam.Transfer aliquots of freshlyreconstituted controls into emptylabeled snap-cap bottles. Attach thesupplied labels to the additionalbottles. Store the aliquotsimmediately at -20°C. Performonly one calibration procedure peraliquot.</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalencecomparison

The following table compares the Elecsys PreciControl ThyroAB with the predicate device.

<table><tr><td>Control Comparison</td></tr><tr><td>Characteristic Elecsys PreciControl ThyroAB Predicate Device BRAHIMS LUMItEST TRAK human Assay (K033454)</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Used for quality control of theElecsys Anti-TSHR immunoassayon the Elecsys and cobas eimmunoassay analyzers.</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Levels</td><td rowspan=1 colspan=1>Two</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Format</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human serum</td><td rowspan=1 colspan=1>same</td></tr><tr><td rowspan=1 colspan=1>Stability</td><td rowspan=1 colspan=1>Unopened:Store at 2 - 8°C until expirationdate.Reconstituted:On the analyzers at 20  25°C: upto 3 hoursAt -20°C: up to 3 months (freezeonly once.After thawing: use only once.</td><td rowspan=1 colspan=1>N/A</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentrationPC 1</td><td rowspan=1 colspan=1>4 IU/L Anti-TSHR antibody (human)</td><td rowspan=1 colspan=1>Negative, indeterminate(actual concentration not given)</td></tr><tr><td rowspan=1 colspan=1>AnalyteConcentrationPC 2</td><td rowspan=1 colspan=1>16 IU/L Anti-TSHR antibody(human)</td><td rowspan=1 colspan=1>Positive(actual concentration not given)</td></tr></table>

# 510(k) Summary, Continued

Substantial equivalence - comparison

The following table compares the Elecsys PreciControl ThyroAB with the predicate device.

<table><tr><td rowspan=1 colspan=3>Control Comparison, continued</td></tr><tr><td rowspan=1 colspan=1>Characteriste</td><td rowspan=1 colspan=1>Elecsys PreciControl ThyroAB</td><td rowspan=1 colspan=1>Predicate DeviceBRAHMS LUMIIeSt TRAKhuman Assay (K033454)</td></tr><tr><td rowspan=1 colspan=1>Handling</td><td rowspan=1 colspan=1>Dissolve contents of one bottle byadding exactly 2.0 mL of distilledwater and allow to stand closed for15 minutes to reconstitute. Mixcarefully, avoiding the formation offoam.Transfer aliquots of freshlyreconstituted controls into emptylabeled snap-cap bottles. Attach thesupplied labels to the additionalbottles. Store the aliquotsimmediately at -20°C. Perform onlyone control procedure per aliquot.</td><td rowspan=1 colspan=1>N/A</td></tr></table>

Roche Diagnostics Corp.   
c/o Ms. Stephanie Greeman Regulatory Affairs Consultant 9115 Hague Road   
Box 50416   
Indianapolis, IN 46250-0416

Re: k080092 Trade/Device Name: Elecsys Anti-HSHR Immunoassay Elecsys PreciControl ThyroAB Regulation Number: 21 CFR 866.5870 Regulation Name: Thyroid autoantibody immunological test system Regulatory Class: Class II Product Code: JZO, JJX Dated: June 17, 2008 Reccived: June 19, 2008

Dear Ms. Greeman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

Ifyour device i clasfied (ee above) into eitherclass I (Special ontrols) r lass II (MA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all  Act' requiements, incding, but not lmite to:gistration and listing (1CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality ystems (QS) regulation (21 CFR Part 820). This letter will llow you to bein marketing your device as described in your Section 510(k) premarket notification. The FDA finding

Page 2 -

of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0450. Also, please note the regulation entitled, "Misbranding by rcference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillancc, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Rcporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address htp://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Maria M. Chan, Ph.D.   
Acting Division Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indication for Use - Elecsys Anti-TSHR Immunoassay

510(k) Number (ifknown): K080092

Device Name: Elecsys Anti-TSHR Immunoassay

Indication For Use:

Immunoassay for the in vitro quantitative determination of autoantibodies to TSH receptor in human serum using a human thyroid stimulating monoclonal antibody. The anti-TSH receptor determination is used in the assessment of patients with suspect Graves' disease (autoimmune hyperthyroidism).

The electrochemiluminescence immunoassay "ECLIA" is intended for use on Elecsys and cobas e immunoassay analyzers.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Manai M Chon

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# Indication for Use - Elecsys PreciControl ThyroAB

510g) Numbe oa K80092

Device Name: Elecsys PreciControl ThyroAB

Indication For Use:

Elecsys PreciControl ThyroAB is used for quality control of the Elecsys Anti-TSHR immunoassay on the Elecsys and cobas e immunoassay analyzers.

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

mana  Chan

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

![](images/709d5ae9d112e9462942ee351ddf7d271b826939fe207a3b17427aac8de0219e.jpg)